A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus.
This study is designed to understand how the body handles the investigational drug, and to
measure the quantity of LY2605541 in fat tissue. The study has two parts. It involves
intravenous (IV) infusion of the investigational drug and a procedure to measure
concentrations in the fat tissue. Both parts of the study will be conducted in participants
with type 1 diabetes mellitus (T1DM). Part A and B of the study might take up to 7 weeks to
complete.